Stemline Therapeutics Inc (STML.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
- private equity
- third-party document and information retrieval
- and much, much more…
|51||2003||Chairman of the Board, President, Chief Executive Officer|
|52||2013||Chief Operating Officer|
|56||2014||Chief Accounting Officer, Vice President - Finance|
- BRIEF-Stemline Therapeutics reports Q3 loss per share $0.68
- BRIEF-Stemline Therapeutics Inc - phase 2 trial of SL-401 has met its primary endpoint
- BRIEF-Stemline Therapeutics files for mixed shelf offering of up to $175 mln
- BRIEF-Stemline Therapeutics Q2 loss per share $0.66
- BRIEF-Stemline Therapeutics presents SL-401 updated stage 1 and 2 data from ongoing pivotal trial in BPDCN